Target Name: SLC2A1
NCBI ID: G6513
Review Report on SLC2A1 Target / Biomarker Content of Review Report on SLC2A1 Target / Biomarker
SLC2A1
Other Name(s): GLUT1DS | Solute carrier family 2, facilitated glucose transporter member 1 | hepG2 glucose transporter | human T-cell leukemia virus (I and II) receptor | choreoathetosis/spasticity | receptor for HTLV-1 and HTLV-2 | solute carrier family 2 member 1 | CSE | GLUT1 | Glucose transporter type 1, erythrocyte/brain | CSE__1433 | HepG2 glucose transporter | Solute carrier family 2 member 1 | DYT18 | choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity) | GLUT-1 | solute carrier family 2 (facilitated glucose transporter), member 1 | episodic (paroxysmal choreoathetosis/spasticity) | glucose transporter type 1, erythrocyte/brain | DYT17 | HTLVR | DYT9 | SDCHCN | EIG12 | PED | GLUT | dystonia gene 9 | Receptor for HTLV-1 and HTLV-2 | GTR1_HUMAN | dystonia gene 18

GLUT1DS: A GLucose Transport Protein Implicated in Cancer and Neurodegenerative Diseases

GLUT1DS, also known as SLC2A1, is a gene that encodes a protein known as GLUT1-associated protein 1. This protein is expressed in many different tissues throughout the body and is involved in a variety of cellular processes.

One of the key functions of GLUT1DS is its role in the transport of glucose into the brain. The brain is one of the body's most important organs and relies heavily on the delivery of oxygen and nutrients to maintain its health. In order to do this, the brain needs to be able to efficiently import glucose, which is a critical energy source.

GLUT1DS helps to regulate the movement of glucose into the brain by allowing it to interact with a protein called GLUT1. GLUT1 is a transmembrane protein that is expressed in many different tissues, including the brain. It plays a key role in the regulation of glucose uptake and release, as well as the transport of other molecules into the cell.

In addition to its role in glucose transport, GLUT1DS is also involved in the regulation of a variety of other cellular processes. For example, it has been shown to be involved in the regulation of cell division, and has been shown to play a role in the development of cancer.

As a drug target, GLUT1DS is an attractive target for researchers because of its involvement in a variety of cellular processes that are important for human health. It is also a good candidate for a biomarker, as its expression has been shown to be associated with a number of diseases, including cancer, diabetes, and neurodegenerative diseases.

In conclusion, GLUT1DS is a gene that encodes a protein that is involved in a variety of cellular processes, including the regulation of glucose transport and the development of cancer. As a drug target, it is an attractive target for researchers because of its involvement in these processes, as well as its potential as a biomarker. Further research is needed to fully understand the role of GLUT1DS in human health and disease.

Protein Name: Solute Carrier Family 2 Member 1

Functions: Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake (PubMed:18245775, PubMed:19449892, PubMed:25982116, PubMed:27078104, PubMed:10227690). Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses (PubMed:18245775, PubMed:19449892). Most important energy carrier of the brain: present at the blood-brain barrier and assures the energy-independent, facilitative transport of glucose into the brain (PubMed:10227690). In association with BSG and NXNL1, promotes retinal cone survival by increasing glucose uptake into photoreceptors (By similarity)

The "SLC2A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC2A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SLC2A1-DT | SLC2A10 | SLC2A11 | SLC2A12 | SLC2A13 | SLC2A14 | SLC2A2 | SLC2A3 | SLC2A3P1 | SLC2A4 | SLC2A4RG | SLC2A5 | SLC2A6 | SLC2A7 | SLC2A8 | SLC2A9 | SLC2A9-AS1 | SLC30A1 | SLC30A10 | SLC30A2 | SLC30A3 | SLC30A4 | SLC30A4-AS1 | SLC30A5 | SLC30A6 | SLC30A7 | SLC30A8 | SLC30A9 | SLC31A1 | SLC31A2 | SLC32A1 | SLC33A1 | SLC34A1 | SLC34A2 | SLC34A3 | SLC35A1 | SLC35A2 | SLC35A3 | SLC35A4 | SLC35A5 | SLC35B1 | SLC35B2 | SLC35B3 | SLC35B4 | SLC35C1 | SLC35C2 | SLC35D1 | SLC35D2 | SLC35D3 | SLC35E1 | SLC35E1P1 | SLC35E2A | SLC35E2B | SLC35E3 | SLC35E4 | SLC35F1 | SLC35F2 | SLC35F3 | SLC35F4 | SLC35F5 | SLC35F6 | SLC35G1 | SLC35G2 | SLC35G3 | SLC35G4 | SLC35G5 | SLC35G6 | SLC36A1 | SLC36A2 | SLC36A3 | SLC36A4 | SLC37A1 | SLC37A2 | SLC37A3 | SLC37A4 | SLC38A1 | SLC38A10 | SLC38A11 | SLC38A2 | SLC38A3 | SLC38A4 | SLC38A4-AS1 | SLC38A5 | SLC38A6 | SLC38A7 | SLC38A8 | SLC38A9 | SLC39A1 | SLC39A10 | SLC39A11 | SLC39A12 | SLC39A13 | SLC39A14 | SLC39A2 | SLC39A3 | SLC39A4 | SLC39A5 | SLC39A6 | SLC39A7 | SLC39A8